文献速递骨软组织肉瘤与黑色素瘤

在参考中心接受手术可改善肉瘤患者的生存:一项全国性研究

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
PubMed 文献 · Ann Oncol · 2019-01-01

NETSARC网络要求全国肉瘤患者经多学科肿瘤委员会(MDTB)讨论和专家病理复核。基于35 784例患者的前瞻性登记数据,在NETSARC中心手术与无复发生存、无事件生存和总生存正相关,总生存的HR为0.681(95%CI 0.618-0.749,P<0.001)。

要点

  • 在NETSARC参考中心手术与更好的无局部复发生存、无事件生存和总生存正相关。
  • 多变量分析中,参考中心手术与总生存正相关,HR为0.681(95%CI 0.618-0.749,P<0.001)。
  • NF1病史是LRFS、EFS和OS最强的 adverse 预后因素之一。

核心结论

  • 这项全国性肉瘤患者登记研究显示,在参考中心接受手术治疗可降低复发和死亡风险。

研究设计与样本

  • 基于法国全国NETSARC登记网络的前瞻性数据收集与监测,纳入全部35 784例患者,并对29 497例新发患者亚组进行分析。
  • NETSARC为包含26个肉瘤参考中心的网络,设有专门的多学科肿瘤委员会(MDTB);自2010年起,全国肉瘤患者须经MDTB讨论和专家病理复核。
  • 进行了描述性分析、单因素和多因素预后因素分析。

主要发现

  • 35 784例患者中报告155种不同组织学亚型,4 310例(11.6%)诊断时已有转移。
  • 既往癌症、既往放疗、1型神经纤维瘤病(NF1)和Li-Fraumeni综合征分别见于12.5%、3.6%、0.7%和0.1%的患者。
  • 29 497例新发患者中,25 851例(87.6%)接受了肉瘤手术切除,其中9 949例(33.7%)在NETSARC中心手术。
  • 在新发患者人群中,部位、分级、年龄、大小、深度、组织学类型、性别、NF1和在NETSARC中心外手术均与总生存(OS)、无局部复发生存(LRFS)和无事件生存(EFS)相关。
  • NF1病史是LRFS、EFS和OS最强的 adverse 预后因素之一;经MDTB讨论与LRFS和EFS改善相关,但若手术未在参考中心进行,则为OS的 adverse 预后因素。

关键数值与推荐

  • 多变量分析中,在NETSARC中心手术与LRFS、EFS和OS正相关(所有P<0.001),OS的风险比HR为0.681(95%CI 0.618-0.749)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry. PATIENTS AND METHODS: Patients' characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497). RESULTS: Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li-Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618-0.749) for OS]. CONCLUSION: This nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Blay JY, Honoré C, Stoeckle E, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019. PMID: 31081028. doi:10.1093/annonc/mdz124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。